Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest announcement is out from Aptose Biosciences ( (TSE:APS) ).
Aptose Biosciences has reported promising early results from their TUSCANY trial, involving the TUS+VEN+AZA triplet therapy for newly diagnosed AML patients. The trial, which uses a combination of tuspetinib, venetoclax, and azacitidine, has shown complete remissions in patients with TP53-mutated and FLT3-wildtype AML, demonstrating favorable safety and efficacy. These results indicate a potential new frontline treatment for a diverse group of AML patients, enhancing Aptose’s position in the oncology field and offering hope for stakeholders.
More about Aptose Biosciences
Aptose Biosciences Inc. is a clinical-stage precision oncology company focused on developing therapies for patients with acute myeloid leukemia (AML). They are working on innovative treatments targeting various mutations in AML patients who are ineligible for induction chemotherapy.
YTD Price Performance: -25.00%
Average Trading Volume: 7,012,900
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $11.37M
See more data about APS stock on TipRanks’ Stock Analysis page.
